Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB, Peyrade F, Krauss J, Mesía R, Remenar E, Gauler TC, Keilholz U, Delord JP, Schafhausen P, Erfán J, Brümmendorf TH, Iglesias L, Bethe U, Hicking C, Clement PM. Vermorken JB, et al. Among authors: krauss j. Ann Oncol. 2014 Mar;25(3):682-688. doi: 10.1093/annonc/mdu003. Ann Oncol. 2014. PMID: 24567516 Free PMC article. Clinical Trial.
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck.
Machiels JP, Specenier P, Krauß J, Dietz A, Kaminsky MC, Lalami Y, Henke M, Keilholz U, Knecht R, Skartved NJ, Horak ID, Pamperin P, Braun S, Gauler TC. Machiels JP, et al. Among authors: krauss j. Cancer Chemother Pharmacol. 2015 Jul;76(1):13-20. doi: 10.1007/s00280-015-2761-4. Epub 2015 May 8. Cancer Chemother Pharmacol. 2015. PMID: 25952795 Clinical Trial.
Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study.
Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, Fischer R, Hamann S, Strumberg D, Mross KB. Schultheis B, et al. Among authors: krauss j. Ann Oncol. 2013 Jun;24(6):1560-7. doi: 10.1093/annonc/mdt056. Epub 2013 Mar 13. Ann Oncol. 2013. PMID: 23493136 Free PMC article. Clinical Trial.
Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K. Strumberg D, et al. Among authors: krauss j. Invest New Drugs. 2012 Jun;30(3):1138-43. doi: 10.1007/s10637-010-9619-8. Epub 2010 Dec 21. Invest New Drugs. 2012. PMID: 21170759 Clinical Trial.
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, Schaefer PL, Dakhill SR, Jaeckle KA. Uhm JH, et al. Among authors: krauss jc. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):347-53. doi: 10.1016/j.ijrobp.2010.01.070. Epub 2010 May 25. Int J Radiat Oncol Biol Phys. 2011. PMID: 20510539 Free PMC article. Clinical Trial.
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K. Strumberg D, et al. Among authors: krauss j. Int J Clin Pharmacol Ther. 2010 Jul;48(7):473-5. doi: 10.5414/cpp48473. Int J Clin Pharmacol Ther. 2010. PMID: 20557849 Clinical Trial. No abstract available.
First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma.
Massard C, Soria JC, Krauss J, Gordon M, Lockhart AC, Rasmussen E, Upreti VV, Patel S, Ngarmchamnanrith G, Henary H. Massard C, et al. Among authors: krauss j. Cancer Chemother Pharmacol. 2019 Jun;83(6):1057-1063. doi: 10.1007/s00280-019-03796-4. Epub 2019 Mar 26. Cancer Chemother Pharmacol. 2019. PMID: 30915497 Clinical Trial.
Pharmacokinetic study of S-1.
Mende B, Krauss J, Thyssen D, Kredtke S, Scheulen ME, Strumberg D, Hanauske A, Makris L, Scigalla P, Urrea PD, Hilger RA. Mende B, et al. Among authors: krauss j. Int J Clin Pharmacol Ther. 2009 Jan;47(1):65-7. doi: 10.5414/cpp47065. Int J Clin Pharmacol Ther. 2009. PMID: 19203542 No abstract available.
1,156 results